STAAR Surgical Company

STAAR Surgical Company is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. STAAR Surgical Company is not very popular among insiders. STAAR Surgical Company is a mediocre stock to choose.

STAAR Surgical Co. engages in the development, manufacture, production, market, and trade of implant...

News

Declining Stock and Decent Financials: Is The Market Wrong About STAAR Surgical Company (NASDAQ:STAA)?

Simply Wall St With its stock down 19% over the past three months, it is easy to disregard STAAR Surgical (NASDAQ:STAA). However...\n more…

Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates

Simply Wall St STAAR Surgical Company ( NASDAQ:STAA ) investors will be delighted, with the company turning in some strong numbers...\n more…

STAAR Surgical Second Quarter 2024 Earnings: Beats Expectations

Simply Wall St STAAR Surgical ( NASDAQ:STAA ) Second Quarter 2024 Results Key Financial Results Revenue: US$99.0m (up 7.3% from 2Q...\n more…

STAA Stock Earnings: Staar Surgical Misses EPS, Beats Revenue for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nSTAA stock results show that Staar Surgical missed analyst estimates for earnings per share but beat on revenue for the second quarter...\n more…

STAAR Surgical Reports Second Quarter 2024 Results

Business Wire STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer Lenses (EVO ICL) for myopia, astigmatism and presbyopia, today reported...\n more…

STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear

Simply Wall St When close to half the companies in the Medical Equipment industry in the United States have price-to-sales ratios (or...\n more…